Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
8.19
+0.20 (2.50%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.03 | 0.04 | 0.06 | 0.13 | 84.68 | 10.65 | |
Revenue Growth | -55.00% | -40.98% | -53.08% | -99.85% | 695.15% | 37.31% |
Gross Profit | 0.03 | 0.04 | 0.06 | 0.13 | 84.68 | 10.65 |
Selling, General & Admin | 40.43 | 45.14 | 52.04 | 66.98 | 117.31 | 89.06 |
Research & Development | 156.5 | 158.68 | 171.6 | 182.95 | 159.19 | 138.69 |
Other Operating Expenses | -6.45 | -5.49 | -4.65 | -4.3 | -4.86 | -3.53 |
Operating Expenses | 190.49 | 198.32 | 218.99 | 245.63 | 271.64 | 224.22 |
Operating Income | -190.46 | -198.29 | -218.93 | -245.5 | -186.96 | -213.57 |
Interest & Investment Income | 10.32 | 13.08 | 24.07 | 23.45 | 7.05 | 1.17 |
Other Non Operating Income (Expenses) | -1.96 | -19.83 | 0.89 | 1.85 | 1.89 | 0.1 |
EBT Excluding Unusual Items | -182.1 | -205.04 | -193.98 | -220.2 | -178.02 | -212.31 |
Gain (Loss) on Sale of Investments | 0.03 | - | -13 | -12.92 | -5 | -36.7 |
Gain (Loss) on Sale of Assets | 0.3 | -3.34 | -1.34 | -1.51 | -0.1 | -1.21 |
Asset Writedown | - | -1.44 | -51.3 | - | - | - |
Other Unusual Items | -0.37 | 1.71 | 3.8 | - | - | - |
Pretax Income | -248.48 | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 |
Net Income | -248.48 | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 |
Net Income to Common | -248.48 | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 21 | 17 | 13 | 13 | 12 | 7 |
Shares Outstanding (Diluted) | 21 | 17 | 13 | 13 | 12 | 7 |
Shares Change | 49.16% | 30.74% | 4.18% | 1.58% | 81.79% | 925.18% |
EPS (Basic) | -11.82 | -16.06 | -26.23 | -18.70 | -14.82 | -36.82 |
EPS (Diluted) | -11.82 | -16.06 | -26.23 | -18.70 | -14.82 | -36.82 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -133.97 | -150.8 | -162.86 | -166.38 | -193.83 | -191.75 |
Free Cash Flow Per Share | -6.37 | -8.82 | -12.46 | -13.26 | -15.69 | -28.22 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -705411.11% | -550791.67% | -358906.56% | -188845.39% | -220.77% | -2005.31% |
Profit Margin | -920285.18% | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% |
Free Cash Flow Margin | -496188.89% | -418900.00% | -266980.33% | -127984.62% | -228.89% | -1800.50% |
EBITDA | -180.94 | -186.75 | -199.3 | -225.25 | -168.94 | -199.94 |
EBITDA Margin | - | - | - | - | -199.49% | - |
D&A For EBITDA | 9.52 | 11.54 | 19.63 | 20.25 | 18.02 | 13.62 |
EBIT | -190.46 | -198.29 | -218.93 | -245.5 | -186.96 | -213.57 |
EBIT Margin | - | - | - | - | -220.77% | - |